TIP in Patients Affected by Metastatic TNBC
Recruiting
- Conditions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 100
- Registration Number
- NCT05831553
- Locations
- ๐ฎ๐น
Ospedale Santo Stefano, Prato, FI, Italy
๐ฎ๐นIRCCS Istituto Europeo di Oncologia IEO, Milano, MI, Italy
๐ฎ๐นFondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, RM, Italy
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Phase 2
Active, not recruiting
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- ๐ฎ๐น
I.R.S.T. Srl Irccs, Meldola, Italy
๐ฎ๐นOspedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
๐ฎ๐นI.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
ยฉ Copyright 2024. All Rights Reserved by MedPath